Fire patienter afbrød på grund af bivirkninger, to (5, 4%) i bosentangruppen og to (11, 8%) i placebogruppen.
Four patients discontinued due to adverse events, two (5.4%) in the bosentan group and two (11.8%) in the placebo group.